NCT Number: NCT00414323
Evaluation of the Effects of Duloxetine on Norepinephrine
The purpose of this study is to evaluate how taking duloxetine 60mg every day affects the transfer of two normal body chemicals, 3,4-dihydroxyphenylglycol (DHPG) and norepinephrine (NE), across cells in blood and cerebrospinal fluid.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Healthy subjects between the ages of 18-65 years are nonsmokers or are willing to refrain from smoking and are not taking concomitant medications which may inhibit or induce CYP1A2 or CYPD6 or is an MAOI.
Treatment and study plan
Escitalopram
DrugPlacebo
DrugPrimary outcomes
-
Concentrations of DHPG and NE in plasma (in sitting and standing positions), urine, and CSF after multiple daily doses (steady state).
Secondary outcomes
-
Effect of duloxetine versus escitalopram on ex vivo reuptake inhibition of NE and F-hydroxytryptamine (5-HT) in serum and relationship to exposure.
-
Effect of duloxetine versus escitalopram on heart rate variability.
-
Ratio of duloxetine exposure in plasma to CSF at steady state.
-
Relationship between DHPG and NE concentrations and duloxetine exposure in CSF and plasma.
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Registry information
Official study title
Evaluation of the Effects of Duloxetine on Norepinephrine Transporter Inhibition in Healthy Subjects
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- Dec 21, 2006
- Registry last updated
- Jun 12, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
CBT+ for Depression
NCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsIndividualized (fMRI-guided) TMS Treatment for Depression
NCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsA Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
NCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial DetailsProbing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression
NCT05224063
Depressive Disorder, Depressive Disorder, Major
Stanford, California, United States
View Trial Details